Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8461191
APP PUB NO 20110160259A1
SERIAL NO

12956969

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INFINITY PHARMACEUTICALS INC1100 MASSACHUSETTS AVE CAMBRIDGE MA 02138

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Castro, Alfredo C Winchester, US 131 2651
Holson, Edward B Newton Highlands, US 11 111
Hopkins, Brian T Newton, US 48 320
Koney, Nii O New York, US 8 90
Snyder, Daniel A Somerville, US 63 1357
Tibbitts, Thomas T Westford, US 30 231

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 11, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00